Next Article in Journal
StABI5 Involved in the Regulation of Chloroplast Development and Photosynthesis in Potato
Next Article in Special Issue
Manipulating the In Vivo Behaviour of 68Ga with Tris(Hydroxypyridinone) Chelators: Pretargeting and Blood Clearance
Previous Article in Journal
Local and Systemic Humoral Response to Autologous Lineage-Negative Cells Intrathecal Administration in ALS Patients
Previous Article in Special Issue
Associative Interactions among Zinc, Apolipoprotein E, and Amyloid-β in the Amyloid Pathology
Review

Current Biomedical Use of Copper Chelation Therapy

1
Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, via E. Chianesi 53, 00144 Rome, Italy
2
Department of Medical Surgical Sciences and Biotechnologies, University of Rome “La Sapienza”, C.so della Repubblica 79, 04100 Latina, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(3), 1069; https://doi.org/10.3390/ijms21031069
Received: 9 January 2020 / Revised: 3 February 2020 / Accepted: 4 February 2020 / Published: 6 February 2020
(This article belongs to the Special Issue Advances on Chelation in Medicine)
Copper is an essential microelement that plays an important role in a wide variety of biological processes. Copper concentration has to be finely regulated, as any imbalance in its homeostasis can induce abnormalities. In particular, excess copper plays an important role in the etiopathogenesis of the genetic disease Wilson’s syndrome, in neurological and neurodegenerative pathologies such as Alzheimer’s and Parkinson’s diseases, in idiopathic pulmonary fibrosis, in diabetes, and in several forms of cancer. Copper chelating agents are among the most promising tools to keep copper concentration at physiological levels. In this review, we focus on the most relevant compounds experimentally and clinically evaluated for their ability to counteract copper homeostasis deregulation. In particular, we provide a general overview of the main disorders characterized by a pathological increase in copper levels, summarizing the principal copper chelating therapies adopted in clinical trials. View Full-Text
Keywords: copper; chelation therapy; therapeutic chelation; metal homeostasis; cancer; metalloproteins copper; chelation therapy; therapeutic chelation; metal homeostasis; cancer; metalloproteins
Show Figures

Graphical abstract

MDPI and ACS Style

Baldari, S.; Di Rocco, G.; Toietta, G. Current Biomedical Use of Copper Chelation Therapy. Int. J. Mol. Sci. 2020, 21, 1069. https://doi.org/10.3390/ijms21031069

AMA Style

Baldari S, Di Rocco G, Toietta G. Current Biomedical Use of Copper Chelation Therapy. International Journal of Molecular Sciences. 2020; 21(3):1069. https://doi.org/10.3390/ijms21031069

Chicago/Turabian Style

Baldari, Silvia, Giuliana Di Rocco, and Gabriele Toietta. 2020. "Current Biomedical Use of Copper Chelation Therapy" International Journal of Molecular Sciences 21, no. 3: 1069. https://doi.org/10.3390/ijms21031069

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop